MicroRNA-155 influences cell damage in ischemic stroke via TLR4/MYD88 signaling pathway

被引:13
|
作者
Chen, Wei [1 ]
Wang, Lingtong [1 ]
Liu, Zhaoping [2 ]
机构
[1] Linhai Second Peoples Hosp, Dept Neurol, Taizhou 317016, Zhejiang, Peoples R China
[2] Xiangnan Univ, Affiliated Hosp 1, Chenzhou Peoples Hosp 1, Dept Rehabil Med, Chenzhou 423000, Hunan, Peoples R China
基金
芬兰科学院;
关键词
MiR-155; tlr4; myd88; ischemic stroke; cell damage; MIR-155; INJURY; INFLAMMATION; OUTCOMES;
D O I
10.1080/21655979.2021.1935066
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cerebral ischemic stroke (CIS) is extremely harmful, and its treatment should be underpinned by understanding its pathogenic mechanism. This study was designed to determine the involvement of miR-155 in CIS development via the TLR4/MyD88 signaling pathway. First, we quantified serum miR-155 in patients with CIS and healthy individuals, and found high expression of miR-155 in such patients and a decrease in it in the patients after therapy (P < 0.05). Serum miR-155 demonstrated a favorable function in predicting the development and prognosis of CIS (P < 0.001). We also conducted a mouse assay, and found that knocking out miR-155 can improve the neurological function of mice and suppress protein TLR4 and MyD88 (all P < 0.05). Finally, we carried out a cell assay, and found enhancement in the activity of SH-SY5Y cells, decrease in their apoptosis, and protein TLR4 and MyD88 in them after suppression of miR-155 (all P < 0.05). Furthermore, we also found complete reverse by TLR4/MyD88 pathway inhibitor on the influence of increasing miR-155 on cells (P > 0.05). Therefore, with an increase in cases with CIS, miR-155 takes a part in the development of cell damage by activating TLR4/MyD88, and it is probably the key to diagnosing and treating CIS.
引用
收藏
页码:2449 / 2458
页数:10
相关论文
共 50 条
  • [21] Dioscin alleviates lipopolysaccharide-induced inflammatory kidney injury via the microRNA let-7i/TLR4/MyD88 signaling pathway
    Qi, Meng
    Yin, Lianhong
    Xu, Lina
    Tao, Xufeng
    Qi, Yan
    Han, Xu
    Wang, Changyuan
    Xu, Youwei
    Sun, Huijun
    Liu, Kexin
    Peng, Jinyong
    [J]. PHARMACOLOGICAL RESEARCH, 2016, 111 : 509 - 522
  • [22] Crosstalk between HLA class I and TLR4 mediates pro-inflammatory signaling cascades in endothelial cells via TLR4/MyD88 pathway
    Jin, Y.
    Nevarez-Mejia, J.
    Terry, A.
    Reed, E. F.
    Rozengurt, E.
    [J]. HUMAN IMMUNOLOGY, 2023, 84 : 40 - 40
  • [23] Heparin alleviates LPS-induced endothelial injury by regulating the TLR4/MyD88 signaling pathway
    Liu, Wenxun
    Li, Yan
    Wu, Zhaozhao
    Hai, Kerong
    Wang, Yun
    Zhou, Xiaohong
    Ye, Qingshan
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (06)
  • [24] Lipopolysaccharide induces skin scarring through the TLR4/Myd88 inflammatory signaling pathway in dermal fibroblasts
    Xu, Zhigang
    Cheng, Chuantao
    Zhang, Yangang
    Yang, Danyang
    Jing, Wenwen
    Liu, Xin
    Li, Xiaoli
    [J]. BURNS, 2023, 49 (08) : 1997 - 2006
  • [25] Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling
    Ohnishi, Hidenori
    Tochio, Hidehito
    Kato, Zenichiro
    Orii, Kenji E.
    Li, Ailian
    Kimura, Takeshi
    Hiroaki, Hidekazu
    Kondo, Naomi
    Shirakawa, Masahiro
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (25) : 10260 - 10265
  • [26] TLR4/MyD88 signaling determines the metastatic potential of breast cancer cells
    Wu, Kunlin
    Zhang, Huihao
    Fu, Yajuan
    Zhu, Youzhi
    Kong, Lingjun
    Chen, Ling
    Zhao, Feng
    Yu, Liangfei
    Chen, Xiangjin
    [J]. MOLECULAR MEDICINE REPORTS, 2018, 18 (03) : 3411 - 3420
  • [27] Jianpi Yangxue Qufeng compound alleviates atopic dermatitis via TLR4/MyD88/NF-κB signaling pathway
    Yang, Xuesong
    Wang, Zhimin
    Huang, Hong
    Luo, Guangyun
    Cong, Lin
    Yang, Jianting
    Ye, Jianzhou
    [J]. HELIYON, 2024, 10 (01)
  • [28] MyD88 and TLR4 Expression in Epithelial Ovarian Cancer
    Block, Matthew S.
    Vierkant, Robert A.
    Rambau, Peter F.
    Winham, Stacey J.
    Wagner, Philipp
    Traficante, Nadia
    Toloczko, Aleksandra
    Tiezzi, Daniel G.
    Taran, Florin Andrei
    Sinn, Peter
    Sieh, Weiva
    Sharma, Raghwa
    Rothstein, Joseph H.
    Ramon y Cajal, Teresa
    Paz-Ares, Luis
    Oszurek, Oleg
    Orsulic, Sandra
    Ness, Roberta B.
    Nelson, Gregg
    Modugno, Francesmary
    Menkiszak, Janusz
    McGuire, Valerie
    McCauley, Bryan M.
    Mack, Marie
    Lubinski, Jan
    Longacre, Teri A.
    Li, Zheng
    Lester, Jenny
    Kennedy, Catherine J.
    Kalli, Kimberly R.
    Jung, Audrey Y.
    Johnatty, Sharon E.
    Jimenez-Linan, Mercedes
    Jensen, Allan
    Intermaggio, Maria P.
    Hung, Jillian
    Herpel, Esther
    Hernandez, Brenda Y.
    Hartkopf, Andreas D.
    Harnett, Paul R.
    Ghatage, Prafull
    Garcia-Bueno, Jose M.
    Gao, Bo
    Fereday, Sian
    Eilber, Ursula
    Edwards, Robert P.
    de Sousa, Christiani B.
    de Andrade, Jurandyr M.
    Chudecka-Glaz, Anita
    Chenevix-Trench, Georgia
    [J]. MAYO CLINIC PROCEEDINGS, 2018, 93 (03) : 307 - 320
  • [29] TLR4 and MyD88 Expression in Cancer Stem Cells
    Cooke, A. A.
    Gallagher, M. F.
    O'Toole, S. A.
    Martin, C. M.
    Sheils, O. M.
    O'Leary, J. J.
    [J]. MODERN PATHOLOGY, 2011, 24 : 441A - 441A
  • [30] Significance of TLR4/MyD88 expression in breast cancer
    Chen, Xiangjin
    Zhao, Feng
    Zhang, Huihao
    Zhu, Youzhi
    Wu, Kunlin
    Tan, Guozheng
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (06): : 7034 - 7039